Keel
Metabolic & GLP-1

Retatrutide

Retatrutide is a peptide designed to activate three separate hormone receptors at once, one more than tirzepatide and two more than semaglutide. It's currently in late-stage clinical trials and has not yet been approved by the FDA, though early trial results have reported some of the largest weight reductions seen in this class of medications.

Classification
Triple GIP/GLP-1/glucagon receptor agonist
Format
Injectable solution
Half-Life
Approximately 6 days

What Is Retatrutide?

Retatrutide is a synthetic peptide built to activate three hormone receptors at the same time: GLP-1 and GIP, the same two targets as tirzepatide, plus a third, the glucagon receptor. In early animal research, adding glucagon receptor activity produced greater weight loss and food intake reduction than tirzepatide alone, which is what set retatrutide apart and drove its advancement into human trials.[1]

Retatrutide is still investigational, developed by Eli Lilly and currently working through Phase 3 clinical trials. It has not received FDA approval, so unlike semaglutide and tirzepatide, it isn't yet available as a prescribed medication.

What Retatrutide Is Being Researched For

  • Body Weight

    The primary focus of retatrutide research has been its effect on body weight, with a Phase 2 trial in people with obesity reporting average reductions of up to roughly 24% at 48 weeks with the highest dose tested.[2]

  • Blood Sugar Control

    A separate Phase 2 trial in people with type 2 diabetes evaluated retatrutide's effect on blood sugar regulation alongside its effect on body weight in that population.[3]

  • Additional Metabolic Research

    Because retatrutide activates the glucagon receptor in addition to GLP-1 and GIP, research has also expanded into areas like liver fat, since glucagon signaling is tied to energy expenditure and fat metabolism beyond appetite alone.

How Retatrutide Works

  • Activating Three Receptors at Once

    Research points to retatrutide binding to the GLP-1, GIP, and glucagon receptors simultaneously. The first two are shared with tirzepatide and relate mainly to insulin release and appetite signaling, while the added glucagon receptor activity is thought to contribute an energy expenditure component not present in the other two drugs.[1]

  • Reducing Food Intake and Increasing Energy Use

    Research points to retatrutide's combined receptor activity affecting both how much people eat and how their bodies use energy, a combination researchers have proposed as part of why its trial results have shown larger weight reductions than single or dual receptor medications.[1][2]

  • Lasting About a Week in the Body

    Research points to structural modifications that extend retatrutide's activity to roughly six days, supporting once-weekly dosing in the trials conducted so far.[2]

Reconstitution and Handling

Because retatrutide is not yet an approved medication, it's currently only available through clinical trials or as a research-grade compound sold as lyophilized powder, which requires reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Retatrutide's defining feature is its triple-receptor mechanism, adding glucagon receptor activity on top of the GLP-1 and GIP targets shared with tirzepatide. Separate Phase 2 trials in obesity and type 2 diabetes have reported larger average weight reductions than either of the two already-approved medications in this space, though it remains investigational and has not yet completed the FDA approval process. Research continues to expand into related areas like liver fat and blood sugar regulation.

Clinical Overview

Evidence Summary

  • RCT

    In a Phase 2 trial in adults with obesity, retatrutide produced mean weight reductions of up to approximately 24% at 48 weeks with the highest dose, among the largest reported for any agent in this class; the compound remains investigational and is not FDA-approved.[2]

  • RCT

    In a separate Phase 2 trial in adults with type 2 diabetes, retatrutide improved glycemic control and reduced body weight relative to placebo and to an active comparator.[3]

  • RCT

    In a Phase 2 substudy of adults with metabolic dysfunction-associated steatotic liver disease, retatrutide markedly reduced liver fat content, consistent with the added glucagon-receptor component of its mechanism.[5]

  • Animal

    In preclinical models, combined GIP, GLP-1, and glucagon receptor agonism produced greater weight loss and food-intake reduction than dual GIP/GLP-1 agonism, providing the rationale for the triple-agonist design.[1]

Pharmacokinetics

  • Route

    Administered as a once-weekly subcutaneous injection in clinical trials; no marketed formulation exists because the compound is investigational.[4]

  • Half-Life

    First-in-human studies report a mean terminal half-life of approximately 6 days, supporting the once-weekly dosing used in trials.[4]

  • Time to Steady State

    Steady-state exposure is expected after roughly 4 to 5 weeks of once-weekly dosing based on the reported half-life; the trials employ stepwise dose escalation to improve gastrointestinal tolerability.[4]

  • Metabolism and Clearance

    As an acylated peptide, retatrutide is expected to be cleared by proteolytic degradation and fatty-acid beta-oxidation with albumin binding prolonging exposure; detailed human mass-balance and organ-specific clearance data are not yet published.[4]

Contraindications and Interactions

  • Investigational agent not approved by the FDA; any use outside a regulated clinical trial is unapproved and unlicensed, and human safety data are incomplete.[4]
  • As a class consideration for incretin receptor agonists, medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 are theoretical concerns pending long-term safety data; retatrutide has no approved labeling.
  • Pancreatitis is a recognized class concern; no approved labeling governs use in patients with a history of pancreatitis.
  • Glucagon-receptor agonism can raise heart rate and may increase hepatic glucose output, a theoretical concern in patients with cardiovascular disease or poorly controlled diabetes.[2]
  • Delayed gastric emptying may alter absorption of concomitant oral medications, as reported for the incretin agonist class.
  • No published human data address safety in pregnancy or lactation; trials required effective contraception for participants of childbearing potential.

Monitoring Parameters

  • Trials tracked HbA1c and fasting glucose in participants treated for glycemic control, with attention to hypoglycemia when combined with insulin or sulfonylureas.[3]
  • Increases in heart rate have been reported in trials, so heart rate and blood pressure are relevant parameters.[2]
  • Symptoms of pancreatitis are relevant to clinical assessment given the class concern; persistent severe abdominal pain warrants evaluation.
  • Persistent gastrointestinal symptoms, hydration, and renal function are relevant given the reported gastrointestinal adverse events.[2]
  • Liver enzymes and lipids are relevant given the glucagon-receptor-mediated metabolic effects reported in trials.[5]
  • Trial protocols defined a visit cadence for adverse-event capture, consistent with the investigational status.[4]

Reported Adverse Events

  • Nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.[2]
  • Decreased appetite.[2]
  • Increased heart rate.[2]
  • Hypoglycemia when used with background glucose-lowering therapy.[3]

Frequently Asked Questions

What Makes Retatrutide Different from Tirzepatide?

Retatrutide activates a third receptor, glucagon, in addition to the GLP-1 and GIP receptors that tirzepatide targets. This third target is the main focus of current research interest.

Is Retatrutide FDA-Approved?

No. It's currently in Phase 3 clinical trials and has not been approved for any use as of now.

How Much Weight Loss Has Retatrutide Shown in Trials?

Its Phase 2 obesity trial reported average reductions of up to roughly 24% of body weight at 48 weeks with the highest dose tested, among the largest reported for any drug in this class to date.

How Does Retatrutide Work?

Research points to it activating three separate hormone receptors at once, GLP-1, GIP, and glucagon, combining effects on appetite, insulin release, and energy use.

Sources and Research

  1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.
  2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
  3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881.
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048.

Related Reading

For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.